Skip to
  1. Homepage
  2. Rare diseases
  3. Search
Simple search

Simple search

*
(*) mandatory field





 

Other search option(s)

Sickle cell anemia

Orpha number ORPHA232
Synonym(s) Sickle cell disease
Prevalence 1-5 / 10 000
Inheritance Autosomal recessive
Age of onset All ages
ICD-10
  • D57.0
  • D57.1
  • D57.2
ICD-O -
OMIM
UMLS
  • C0002895
MeSH
  • D000755
MedDRA
  • 10040641
SNOMED CT
  • 127040003
  • 417357006

Summary

Sickle cell anemias are chronic hemolytic diseases that may induce three types of acute accidents: severe anemia, severe bacterial infections, and ischemic vasoocclusive accidents (VOA) caused by sickle-shaped red blood cells obstructing small blood vessels and capillaries. Many diverse complications can occur. The prevalence of sickle cell carriers in 25 European states is estimated at about 1/150. In central and western Africa (15-25%), in the French West Indies (10-15%) and in Mediterranean areas (1-15%) a high prevalence is observed in areas that are or have been affected by malaria, because the trait offers protection against pernicious malaria. The presence of fetal hemoglobin means that the disease doesn't manifest until after 3 months. Clinical manifestations are extremely variable between individuals and at different times. In addition to anemia and bacterial infections, VOAs cause hyperalgic focal ischemia (and sometimes infarction) when they occur in the muscles or skeleton. Over the course of time, VOAs may compromise the integrity of tissues or organs. Transmission is autosomal recessive. Sickle cell anemia is determined by combinations of two abnormal alleles of the beta globin gene among which at least one carries the beta 6 glu-val mutation (Hb S). Individuals who carry the gene for hemoglobin S and the gene for thalassemia beta are affected by thalassodrepanocytosis. The betaS/betaC (beta 6 glu-lys) form is also frequent. Diagnosis is based on analysis of hemoglobin using isoelectric focusing, by HPLC, solubility test (Itano test) and molecular analysis. Screening of healthy carriers by family or by population can be suggested and requires prospective genetic counseling. Differential diagnoses include other hereditary hemolytic diseases. Prenatal diagnosis is possible, after genetic counseling, by molecular analysis of a sample of chorionic villi or amniotic fluid. From birth, management should integrate prevention of infections, pain and eventual complications, with social and psycho-educational support, within multidisciplinary centers that are equipped with intensive care (immediate access to blood transfusion). An orphan drug based on hydroxycarbamide (hydroxyurea) has obtained European marketing authorization for the severe forms of the disease. Regular or occasional transfusions remain an essential therapeutic method. Bone marrow transplantation is indicated in cases with cerebral vasculopathy. The prognosis is difficult to predict. Serious VOA or organ failure can be a cause of death.

Expert reviewer(s)

  • Pr Frédéric GALACTEROS

(*) Required fields.

Attention: Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed.


Captcha image

Detailed information

Clinical practice guidelines
  • FR (2010,pdf)
  • DE (2010)
Article for general public
  • FR (2011,pdf)
  • DE (2010)
Clinical genetics review
  • EN (2012)
Get Acrobat Reader
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.